Loading
Latest filing published 16 Aug 2024 for Biora Therapeutics, INC., €43k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Aditya P. Mohanty (chief executive) discloses dealings in Biora Therapeutics, Inc. to SEC (Form 4). Between 8 November 2021 and 15 August 2024, the trades on record add up to 9 filings.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 16 August 2024 came the latest disclosure, a share grant for €43k in Biora Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations